Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non-Michaelis-Menten P450 Kinetics on Fraction Metabolized.
Basimglurant, a novel mGlu5-negative allosteric modulator under development for the treatment of major depressive disorder, is cleared via cytochrome P450 (P450)-mediated oxidative metabolism. Initial enzyme phenotyping studies indicated that CYP3A4/5 dominates basimglurant metabolism and highlights a risk for drug-drug interactions when it is comedicated with strong CYP3A4/5 inhibitors or inactivators; however, a clinical drug-drug interaction (DDI) study using the potent and selective CYP3A4/5 inhibitor ketoconazole resulted in an area under the curve (AUC) AUCi/AUC ratio of only 1.24. A further study using the CYP3A4 inducer carbamazepine resulted in an AUCi/AUC ratio of 0.69. More detailed in vitro enzyme phenotyping and kinetics studies showed that, at the low concentrations attained clinically, basimglurant metabolic clearance is catalyzed mainly by CYP1A2. The relative contributions of the enzymes were estimated as 70:30 CYP1A2:CYP3A4/5. Using this information, a clinical study using the CYP1A2 inhibitor fluvoxamine was performed, resulting in an AUCi/AUC ratio of 1.60, confirming the role of CYP1A2 and indicating a balanced DDI risk profile. Basimglurant metabolism kinetics show enzyme dependency: CYP1A2-mediated metabolism follows Michaelis-Menten kinetics, whereas CYP3A4 and CYP3A5 follow sigmoidal kinetics [with similar constant (KM) and S50values]. The interplay of the different enzyme kinetics leads to changing fractional enzyme contributions to metabolism with substrate concentration, even though none of the metabolic enzymes is saturated. This example demonstrates the relevance of non-Michaelis-Menten P450 enzyme kinetics and highlights the need for a thorough understanding of metabolism enzymology to make accurate predictions for human metabolism in vivo.
Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Stephen
S
Fowler
Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Elena
E
Guerini
Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
NaHong
N
Qiu
Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Yumi
Y
Cleary
Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Neil
N
Parrott
Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Gerard
G
Greig
Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland navita_l.mallalieu@roche.com.
Navita L
NL
Mallalieu
D000328:Adult; D000368:Aged; D002220:Carbamazepine / Q000494:pharmacology; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D004347:Drug Interactions; D005260:Female; D016666:Fluvoxamine / Q000494:pharmacology; D006801:Humans; D007093:Imidazoles / Q000378:metabolism* / Q000494:pharmacology*; D007654:Ketoconazole / Q000494:pharmacology; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D011725:Pyridines / Q000378:metabolism* / Q000494:pharmacology*; D055815:Young Adult
C000596770:2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine; D007093:Imidazoles; D011725:Pyridines; D002220:Carbamazepine; D003577:Cytochrome P-450 Enzyme System; D016666:Fluvoxamine; D007654:Ketoconazole